What Will the 2013 Specialty Drug Pipeline Bring?
By Angela Maas - December 21, 2012

The FDA has been particularly busy with the specialty drug pipeline the last couple of years. Consequently, payers have been spending a good amount of time analyzing these drugs in order to determine their benefit design strategies.

In 2011, two new hepatitis C oral drugs seemed to get the bulk of the chatter surrounding the specialty pharma pipeline. In addition, the FDA approved a drug for lupus — the first OK’d for that condition in more than 50 years — as well as two oncology drugs that it approved concurrently with a companion diagnostic test.

Over the past year, the FDA approved a slew of oncology therapies, as well as numerous drugs to treat HIV. A drug to treat cystic fibrosis made approval headlines, as did the second oral multiple sclerosis drug and the first oral treatment for rheumatoid arthritis.

Some conditions that may see new specialty approvals in 2013 are metastatic melanoma and multiple sclerosis. What else do you expect to see next year as far as specialty drug approvals?

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?

About the AIS Bloggers
Managing Editor, Health Plan Week
View Patrick's Profile
Managing Editor, Inside Health Insurance Exchanges and The AIS Report on Blue Cross and Blue Shield Plans*
View Steve's Profile
Managing Editor, Medicare Advantage News
View Lauren's Profile
Managing Editor, Specialty Pharmacy News, Drug Benefit News and AIS E-Media
View Angela's Profile
Managing Editor, Report on Medicare Compliance
View Nina's Profile
Editor, Report on Patient Privacy and Report on Research Compliance
View Theresa's Profile
Associate Editor, Report on Patient Privacy and Drug Benefit News
View Lauren's Profile
President & Publisher
View Rick's Profile